meta
|
evidence
oncology
Living systematic review and meta-analysis
NSCLC neoadjuvant setting
1
lung cancer : small cell (SCLC)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
durvalumab based treatment
durvalumab alone
nivolumab based treatment
nivolumab plus SoC
pembrolizumab based treatment
pembrolizumab plus SoC
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
table
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
click on circles to display study description...
powered by
vis.js Network